0001140361-23-040179.txt : 20230817 0001140361-23-040179.hdr.sgml : 20230817 20230817090936 ACCESSION NUMBER: 0001140361-23-040179 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230817 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230817 DATE AS OF CHANGE: 20230817 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PhenomeX Inc. CENTRAL INDEX KEY: 0001689657 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 352415390 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39388 FILM NUMBER: 231179931 BUSINESS ADDRESS: STREET 1: 5858 HORTON STREET STREET 2: SUITE 320 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 510-858-2855 MAIL ADDRESS: STREET 1: 5858 HORTON STREET STREET 2: SUITE 320 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: Berkeley Lights, Inc. DATE OF NAME CHANGE: 20161109 8-K 1 brhc20057670_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported): August 17, 2023
 
PhenomeX Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware
001-39388
35-2415390
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)

5858 Horton Street, Suite 320
  

Emeryville, California
94608
     
(Address of Principal Executive Offices)
(Zip Code)
(510) 858-2855
(Registrant’s telephone number, including area code)
 
Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol
Name of each exchange on which registered
     
Common Stock, $0.00005 par value per share
CELL
The Nasdaq Global Select Market
     
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Item 8.01
Other Events
 
On August 17, 2023, PhenomeX Inc., a Delaware Corporation (the “Company”) announced the execution of an Agreement and Plan of Merger, dated as of August 17, 2023, by and among the Company, Bruker Corporation, a Delaware corporation (“Parent”), and Bird Mergersub Corporation, a Delaware corporation and a direct wholly owned subsidiary of Parent (“Merger Sub”).  A copy of the press release announcing the transaction is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
 
Additional Information about the Transaction and Where to Find It
 
The tender offer described in this Current Report on Form 8-K has not yet commenced, and this communication is neither an offer to purchase nor a solicitation of an offer to sell securities. At the time the tender offer is commenced, Parent and Merger Sub will file a tender offer statement on Schedule TO with the U.S. Securities and Exchange Commission (“SEC”), and the Company will file a solicitation/recommendation statement on Schedule 14D-9 with the SEC.
 
Investors and Company security holders are strongly advised to read the tender offer statement (including the offer to purchase, letter of transmittal and related tender offer documents) that will be filed by Parent and Merger Sub with the SEC and the related solicitation/recommendation statement on Schedule 14D-9 that will be filed by the Company with the SEC, in their entirety when they become available, because they will contain important information, including the terms and conditions of the offer.
 
Once filed, these documents will be available at no charge on the SEC’s website at www.sec.gov or from the information agent that will be named in the tender offer materials.  In addition, a copy of the tender offer statement and other related documents filed with or furnished to the SEC by Parent or Merger Sub may be obtained free of charge on Parent’s website at ir.bruker.com, and a copy of the solicitation/recommendation statement and other related documents filed with or furnished to the SEC may be obtained free of charge on the Company’s website at investors.phenomex.com.
 
Cautionary Note Regarding Forward-Looking Statements
 
This communication contains “forward-looking statements” regarding the potential acquisition of the Company.
 
All statements, other than statements of historical facts, including statements concerning the Company’s plans, objectives, goals, beliefs, strategy and strategic objectives, future events, business conditions, results of operations, financial position, business outlook, business trends and other information, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “potential” “predict,” “project,” “seek,” “should,” “strategy,” “target,” or “will” or the negatives of these terms or variations of them or similar terminology.
 
Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties.
 
Risks and uncertainties include, but are not limited to: the risk that the closing conditions for the proposed transaction will not be satisfied; the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement entered into in accordance with the proposed transaction; uncertainty as to the percentage of Company stockholders that will support the proposed transaction and tender their shares in the offer; the risk of stockholder litigation relating to the proposed transaction, including resulting expense or delay; the possibility that the proposed transaction will not be completed in the expected timeframe or at all; the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of the Company’s common stock; and the risk that the proposed transaction and its announcement could have an adverse effect on the ability of the Company to retain and hire key personnel and to maintain relationships with customers, vendors, employees, stockholders and other business partners and on its operating results and business generally.
 
A further list and descriptions of these risks, uncertainties and other factors can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, including in the sections captioned “SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS” and “Item 1A. Risk Factors,” and in the Company’s subsequent Quarterly Reports on Form 10-Q, and other filings with the SEC. Copies of these filings are available online at www.sec.gov or investors.phenomex.com.

Item 9.01
Financial Statements and Exhibits
 
(d)
Exhibits

Exhibit No.
  
Description
     
 
Press Release, dated August 17, 2023
     
104
  
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date:
August 17, 2023
    
         
   
PHENOMEX INC.
          
   
By:
/s/ Scott Chaplin
     
Name:
Scott Chaplin
     
Title:
Chief Legal Officer

 
EX-99.1 2 brhc20057670_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1

Bruker Corporation and PhenomeX Inc. Announce Definitive Agreement for Bruker to Acquire PhenomeX in All-Cash Transaction
 
Acquisition initiates Bruker’s entry into functional single-cell biology research solutions
 
BILLERICA, Massachusetts and EMERYVILLE, California, August 17, 2023 — Bruker Corporation (Nasdaq: BRKR) and PhenomeX Inc. (Nasdaq: CELL) today announced that they have signed a definitive agreement for Bruker to acquire PhenomeX for $1.00 per share in an all-cash transaction. The proposed acquisition values PhenomeX at a total equity value of approximately $108 million. PhenomeX is a functional cell biology company that provides single-cell biology research tools to deliver deep insights into cellular function and new perspectives on phenomes and genotype-to-phenotype linkages.
 
PhenomeX was formed in early 2023 through the combination of Berkeley Lights and IsoPlexis, and PhenomeX currently has an installed base of more than 400 instruments. PhenomeX provides single-cell biology workflows with instruments, software and molecular biology reagents. The PhenomeX products include the key Beacon® Optofluidic platform, as well as the IsoLight® and IsoSpark® proteomics barcoding platform. The Beacon Optofluidic system enables researchers to accelerate biologics product development by functional characterization of tens of thousands of single cells in parallel, while maintaining the cells in a healthy state for further genomic and proteomic profiling, connecting phenotype with genotype and other multiomic information. The Protein Barcoding Suite includes the IsoLight® and IsoSpark® instruments, which automate multiplexed measurements of the extracellular proteome and of the intracellular proteome of single cells for translational research.
 
Dr. Mark R. Munch, President of the Bruker NANO Group, commented: “The unique single-cell analysis platforms of PhenomeX are enabling researchers to more rapidly and precisely unlock new insights in functional cell biology research leading to important discoveries across the large and rapidly growing markets of antibody therapeutics, cell line development, cell therapy and gene therapy. This acquisition will mark Bruker’s entry into single-cell biology research tools, which complements Bruker’s emerging spatial biology business - in support of our transformational Project Accelerate 2.0 strategy.”
 
“This is an important next step for PhenomeX as we bring together two companies passionate about innovating for our customers to support human health,” said Siddhartha Kadia, PhD, Chief Executive Officer and Director of PhenomeX. “By joining forces with Bruker, a respected and innovative global leader in life science research tools, we will not only enhance PhenomeX’s differentiated, high-value technologies but also our customers’ abilities to discover novel antibodies and accelerate development and manufacturing of cell and gene therapies. I am very proud of the PhenomeX team, and excited to work with our new colleagues at Bruker as we enter our next phase of growth.”

For Bruker, Perella Weinberg Partners acted as financial advisor and Morgan Lewis as legal advisor. For PhenomeX, William Blair & Company, L.L.C. acted as financial advisor and Freshfields Bruckhaus Deringer LLP as legal advisor.

Terms of the Agreement
 
Bruker will commence a tender offer to acquire all outstanding shares of PhenomeX for a purchase price of $1.00 per share in cash, for a total equity value of approximately $108 million. The transaction is not subject to any financing conditions and is expected to close in the fourth quarter of 2023, subject to customary closing conditions. After the tender offer closes, PhenomeX will merge into a wholly owned subsidiary of Bruker, and any shares of PhenomeX that were not tendered in the tender offer will be converted into the right to receive the same per-share consideration as paid in the tender offer.
 
About PhenomeX
 
PhenomeX is empowering scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advance human health. We enable scientists to reveal the most complete insights on cell function and obtain a full view of the behavior of each cell. Our unique suite of proven high-throughput tools and services offer unparalleled resolution and speed, accelerating the insights that are key to advancing discoveries that can profoundly improve the prevention and treatment of disease. Our award-winning platforms are used by researchers across the globe, including those at the top 15 global pharmaceutical companies and approximately 85% of leading U.S. comprehensive cancer centers.
 
About Bruker
 
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life-science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial research, semiconductor metrology and cleantech applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.
 
Cautionary Statement Regarding Forward-Looking Statements
 
This communication contains “forward-looking statements” regarding the potential acquisition of PhenomeX.
 
All statements, other than statements of historical facts, including statements concerning Bruker’s and PhenomeX’s plans, objectives, goals, beliefs, strategy and strategic objectives, future events, business conditions, results of operations, financial position, business outlook, business trends and other information, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “potential” “predict,” “project,” “seek,” “should,” “strategy,” “target,” or “will” or the negatives of these terms or variations of them or similar terminology.
 
2
Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties.
 
Risks and uncertainties include, but are not limited to: the risk that the closing conditions for the proposed transaction will not be satisfied; the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement entered into in accordance with the proposed transaction; uncertainty as to the percentage of PhenomeX stockholders that will support the proposed transaction and tender their shares in the offer; the risk of stockholder litigation relating to the proposed transaction, including resulting expense or delay; the possibility that the proposed transaction will not be completed in the expected timeframe or at all; the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of PhenomeX's common stock; and the risk that the proposed transaction and its announcement could have an adverse effect on the ability of PhenomeX to retain and hire key personnel and to maintain relationships with customers, vendors, employees, stockholders and other business partners and on its operating results and business generally.
 
For further discussion of these and other risks and uncertainties, see Bruker’s and PhenomeX’s most recent Form 10-K and Form 10-Q filings with the SEC. Except as required by law, neither Bruker nor PhenomeX undertakes any duty to update forward-looking statements to reflect events after the date of this press release.
 
Additional Information about the Acquisition and Where to Find It
 
The tender offer described in this communication has not yet commenced, and this communication is neither an offer to purchase nor a solicitation of an offer to sell securities. At the time the tender offer is commenced, Bruker and its acquisition subsidiary will file a tender offer statement on Schedule TO with the SEC, and PhenomeX will file a solicitation/recommendation statement on Schedule 14D-9 with the SEC.
 
Investors and PhenomeX security holders are strongly advised to read the tender offer statement (including the offer to purchase, letter of transmittal and related tender offer documents) that will be filed by Bruker and its acquisition subsidiary with the SEC and the related solicitation/recommendation statement on Schedule 14D-9 that will be filed by PhenomeX with the SEC, in their entirety when they become available, because they will contain important information, including the terms and conditions of the offer.
 
Once filed, these documents will be available at no charge on the SEC’s website at www.sec.gov or from the information agent that will be named in the tender offer materials.  In addition, a copy of the tender offer statement and other related documents filed with or furnished to the SEC by Bruker or its acquisition subsidiary may be obtained free of charge on Bruker’s website at ir.bruker.com, and a copy of the solicitation/recommendation statement and other related documents filed with or furnished to the SEC may be obtained free of charge on PhenomeX’s website at investors.phenomex.com.
 
3
Investor Contact:
Justin Ward
Sr. Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

PhenomeX Investor Contact:
IR@phenomex.com


4
 EX-101.SCH 3 cell-20230817.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 cell-20230817_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 cell-20230817_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document and Entity Information
Aug. 17, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 17, 2023
Entity File Number 001-39388
Entity Registrant Name PhenomeX Inc.
Entity Central Index Key 0001689657
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 35-2415390
Entity Address, Address Line One 5858 Horton Street
Entity Address, Address Line Two Suite 320
Entity Address, City or Town Emeryville
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94608
City Area Code 510
Local Phone Number 858-2855
Title of 12(b) Security Common Stock, $0.00005 par value per share
Trading Symbol CELL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
XML 7 brhc20057670_8k_htm.xml IDEA: XBRL DOCUMENT 0001689657 2023-08-17 2023-08-17 false 0001689657 8-K 2023-08-17 PhenomeX Inc. DE 001-39388 35-2415390 5858 Horton Street Suite 320 Emeryville CA 94608 510 858-2855 false false false false Common Stock, $0.00005 par value per share CELL NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( #))$5<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " R21%7PNOE$N\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M:L,P#(=?9?B>*$Y@?TSJ2\M.&PQ6V-C-V&IK&L?&UDCZ]DN\-F5L#["CI9\_ M?0*U.@CM([Y$'S"2Q70SNJY/0H<5.Q % 9#T 9U*Y93HI^;.1Z=H>L8]!*6/ M:H]05]4M."1E%"F8@458B$RV1@L=49&/9[S1"SY\QB[#C ;LT&%/"7C)@HU3K^2%70*N&*7R6_->K-]9+*NZJ:H[@M^M^6-J!Y$PS]FUQ]^5V'GC=W9 M?VQ\$90M_+H+^0502P,$% @ ,DD15YE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" R21%7X*K>R6$$ S$0 & 'AL+W=OGUHZ.C]U@,MT*^JX@Q379)G*J1%6F=W=FV"B*64'4K,I;" M+RLA$ZJA*=>VRB2C83$HB6W/<;IV0GEJC8?%O9D<#T6N8YZRF20J3Q(J]_\\V MHL?OG&W5V34Q4UD*\6X:S^'(<@P1BUF@C02%KPV;LC@V2L#QSU'4*I]I!IY? MG]2?BLG#9)94L:F(O_%01R.K;Y&0K6@>ZS>Q_<2.$RH Q&KXI-L#WT['8L$ MN=(B.0X&@H2GAV^Z.P;B?$#[P@#O., KN \/*B@?J*;CH11;(DUO4#,7Q52+ MT0#'4[,J^"X"1?WQ*W=T,\QVO_=[@-;"6@5P)ZA5[[@MY4;)@D?TV62DM8PK_KB X* MG7H%D]=W*J,!&UF0N(K)#;/&/WSG=IV?$;YVR=?&U*L +O89JX/#A_=;GQ&( M3@G1054F0! 6%$\Q7==1X.-7-%8,X?!+#O^Z8,R8Y,(D5$@@+6OC@BN5:=24 M1]T2K8L*'G/[B<>,O.;)DLDZ*%S#<=Q6>]#N]Q&>7LG3NX;GC:VYR6R(V2M- M:@.%Z\PBEHJ$_0&[-KA%N/HE5_\:KBFLHJ0QJ(9L1SZS?1T9KN1 N+K]0=?O M(5B#$FMP#19,4LA,R,*<;LA<0W(1(Q_7; P79Q]S8H#CI=![-DMZH1+F[PQ2).X.WV,@HNX+MH=E7% MP<5=_44$$)-9)%*L6C6(P,YL>7W?QXBJLN#B;K[@&BJG6!'7^W'Y$YFS()<0 MK5HL7&DJDJ0P"Q&\WY#OG5LH%(Y/,BK)AL8Y(QF\\*F(2G0K5(7#Q!@X^N$0 M N< V#U?5ZMZQVC0:R2K7-[#/?E_9,]*Y4#6"(C+7@2TSX[ YN^$+]3DLR(Q M6X&0<]L#77DXH1\:6F3%J7@I-)RQB\N(46 S'>#WE1#ZU# '[?)_DO&_4$L# M!!0 ( #))$5>?H!OPL0( .(, - >&PO9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5; M)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/ M3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O M_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_ M/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R! M6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1< M'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72 M[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<' M')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^ M6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ] M?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1 M/,<0F,7XC&894IT,/O'^8* \^>Q\E MTWLJ.?]74_P$4$L#!!0 ( #))$5>7BKL

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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://berkeleylights.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports brhc20057670_8k.htm brhc20057670_ex99-1.htm cell-20230817.xsd cell-20230817_lab.xml cell-20230817_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc20057670_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "brhc20057670_8k.htm" ] }, "labelLink": { "local": [ "cell-20230817_lab.xml" ] }, "presentationLink": { "local": [ "cell-20230817_pre.xml" ] }, "schema": { "local": [ "cell-20230817.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cell", "nsuri": "http://berkeleylights.com/20230817", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc20057670_8k.htm", "contextRef": "c20230817to20230817", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://berkeleylights.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc20057670_8k.htm", "contextRef": "c20230817to20230817", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "trueItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://berkeleylights.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001140361-23-040179-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-23-040179-xbrl.zip M4$L#!!0 ( #))$5> 535]8QH &"K 3 8G)H8S(P,#4W-CT]:U/CN);?MVK_@Y;9>V]W%4G\3&SHIHI.TS/LT, %IF9JO]R2+9GH MMF-G_ "ROW[/D6S'3AQ(($"ZAZFI)K9>1T?GK2/YPR@;A^1N'$;IWIV7A.+C MSBC+)GN]WNWM;1??=./DNF=HFMD349K1R.<[1?U01-_NJ8[%'DVKZG<+]6]- M65MW7;3;SSDTU!/J/_ Q T1[./.Y\OS+P(Y_A?!&(]V2HB82":)^RMKR)U0X!;0GPB<1'6-3+O8.81T8KL67D%[OR)&^4#_[E^8/ M3&;;ALY,S7)]DPZTOL4L7;<#D_<-KT#=77:!5.F7))7%,^)20NGC#@BRO4#< M<0:("T%K',@_'WH-D)9#>!0!G4V' &)"P^.(\;M?^;0&*;,=W=$&?5Y>RG:(8Y=7'G52,)R$@XD.OV8<:KCZ&?$SC/)%/4H_O M%=.1&&B=3E&/2\253X+A#]!IX*)%68:E7XX >L(_D8A1A22.I'$H&/%"8,VJ/(LG>\2:+QQQE$.2V^]FO%TP M\#V\W1 ,(#4SGNR3,4VN1=1!.;%':)[%U:M$C2+?*0D%$U)SDV(.I40QN;:. MB\&3:^^=MDOP__>%K%I1EEDHR^2+VV+"7APR$#>_G1Y?'7TFEU>'5T>7=72_ M)E"71\/?+HZOCH\NR>'I9W+TQ_"7P].?C\CP[.O7X\O+X[/3%X;46 ;I[S0= M@>K+XFB7?.X.NZ#);,M=#MV"?GD BIV#4FW6R+^D6:-.LO>HH[*H#35-5EJ= M@%]X 9QE"_#E[.(K6:I[2D-%&0N5RK$H] M!&P%E>-T?EW4-6^KWK;J%21K&U]M"PZ2X>+H](I<')V?75QM 4#G>9+F%(SA M+":7W$Q(')!MQ+,H3D0D8X@@\ QJ!F7OH9UBLNZ:U2>+Y M^T]Z7]M?#S7KH@*LE'1"H\<".;\4.P=H*2 R+O@D3C+RKGP^HF K\#0C1S?H M<:ABSM[O/.%)62(W]S8'AZU1#IV1@!0Y82A[M!V B&[9I,WT%B[-A M&S/HO3.&%B,$H?XKWK'=&O9 3=&I!W/A@KW[<0?*"YPEEK'Q6DY _'QLM MN14L&^&#]K?*[P+\A7220IWRUPI1E=F*S<)&TF?*DH-:((F4$V0ER 4$I@D MW/ D$SX-RY' UQ&K*O03D%!CQ8TZ\D-8.DX 5TGP\*7&>B8H8K*#F-6%R/& MP 4%IKD@2 )K,/"=@%L#TS1,#__U[?64&4:LT<7/^"2);Q FU&*?>4AO:;(8 M\ZF17(6?WLRM+=]D;+5%L[[W1?LB0@YE'D^:YH;A<[ NJ.5;P&\NM>$?6"%= M']AL0%<*<.D=TS4=Y[E7X+MGFRMZ=UP$NWS).@O+$3BV1IEON%2GEN[JX IZ MGJF!)^@Z+/!6T;NFW3$LW39=;2/K(05;KR'9-B+K'KD&C];[H.2EH$+?YPQ\ MGH3\#[@\*1/**0*MWQ!J[W\840$3'\;CL4A3G"<* :+([DE3W"I>A"D>7UR2 MH_$DC*>PLDTF(Z=Q]^&Y+M"Y^HN[-=)":0F&OH(9]-W;/I;;0C@J.O[B(N$Q M(OR0L82G:?'G1$1:9W'& 8ZU5V/,( M1IW>B#!<\#=V5^1#:86<)>?@P@B9AC3;;#9-2S=M3[=]TW*\ON=2$!H^,*@Q M (O0VH2W-(0E@DJ1H$]BUCK]/))Q%PE]Q?%^2'H]CV&IPO\5DSD/N@^B>&!Y M?6O -,MP H>[#A\8CJ[; ]=B^@HDZUI];3.^V8N)F0>%^@;H;ZTQG@S\#RJA MP?(N"!@]J/,$))J8T) !,O2Y - H*@A'@6?^;E MPNU+92*J[<.$TSDIZ( ![;" !DZ?6ZYG4!=$FNOI!NU3QUQI3]S6%\S3]\LU M]DD,RWT^BJ/%B!FHY3XU+?'$,?[*?@ 89\@A,GD9SY+@&>#G/T0 F%E8%A:^3WO>P(MY+A M:9R1P\DD!-;VT)Y[<0"JC9_'Q3R^@+''$TFU&-4*U"-5\AC6+2!J*Q]\(+0T M24C3C"1RCWIN 1\+ FE*V3D4KH30]KS5]6EY..+^-YG,0"=@\$X2@<$^+[XC M'@_C6\0&%B+.B-/YE00B1)(6*=!WQB,F$XL!4>,\S&C$XSP-IR2EF4B#J6Q9 M-(@]@)N6,4,L2&:[A3GT RL038NR$C%!' (,V!QM<8&1N'3OV7GH!4-*#\>- MB _DEZI4XQ/ UQ4"]]1HDDJ]:HU#/CFKJT@D6:8A?D]$!G2#H=4\*B*-:5U- M^+;);*K9GJM9ED5=;O*^'^C!P.3,M1_CS'EQ''H4*"D#LL8UOS/Z.J[Z0Z;] MRM$1M1_P'ADR ]?I^\SR \TR?<>U M[0'W?<_R34-CQANWKL"M,P23<8'A15;5+=K1C1JW-O(-*UZUM*ZJ^<:N?U%V M/4\XZE8\JB*3I-%$2\Z"H.&+#5S/T;P^=TS-LPR#PH--P4&D/K4,T^R_L>W# M; N([O@U3#^H;76+=8QWWOO5F%C5?6/C-S9&XCI.TYPG[0=ZYV_&C,7=;>9F9\URM!^'FSF;JA( M $\X:R"Z.G@AI681-0#D;DL$X$?*K;6,KML6LG]4;M+\Z4VC.J YQW:/V@=X M.)WP"L_ (\%PZH^49GA"SI9N=P<;RTQ[==0D5(:D+Z=C>/,$K%AZUQC\*%@I M#S!(>N&E' ?13+/FD?=N-Y9DD)F*Y%=SWOJ,Y,Z M 6=V'T\A,$\;! /-X8QRC[K:*KN[PZ.3DV?&](99]K7XH;3NYP[\V53C=M_R MF,YMR[==ESJ61QV'#VR'.LQ\A/.%^J=,.[L"B_>4IHS^27X.8W#)P"@.P2PF M7VGR;3'%]=6SD^Z3?:OI^"W2;-L(\+W<]+( ;YVS^N\\S40PW<2N^''$T/?G MQ)L27^Z0CX'AP!SD\@C,W/:U2 F-" <>O$;;^AJ6+QMA"&&"6]HT)8P'(E(' M8=7&&^B\Q2L$9C<'F.0=3GRP+S??RLHB+3$-HFB"IVDQ?4&%(PRO8ZQX*T'5 M-X8F9NU@$F6WW:,E4WD@)[-L]K-L-52-:L+2YV [^+;E^5K?ZCN>RVP&DPV8 M/Z!>0%?(F7]TI.K[.(R_(F'/&0['P3WDAWE(K;0L%K(P1D"I4KL I4:Q#,'D M*9>U )@BUP-O-A0R+*-N?L(5D6.%4QS\5L#02"H13!!*$GXC\/*YH+QQCE!? MWD2(E?%"2483ELZ$BLSS8,L"0>8[6@6"ZJ3=)7__R1U8UORJ+*Q1*ZHW0P*; M(@*R\J58"_=>U2_%6K@QZY4NQ5HUM\D/.4UDBNBHZDM-1**O>%/=!R;%=!GT M_W1Q_N6<7O-/":??, VRG:4F4*7C89T.#3)$*PUOZ31=TM&2)5&0*.Q+5+;% M\(IWV@SMZ]Y(4,?'@WC\\;=B^N;2K9B-1*./,SXF3E?3MW\'HPU\=3)7WJ;S M<*CS50VW!Y5=#6%KF6QG$9F[F&>7-.Y2V264E)<>D.'LR#)YA^H$$WD- +A^ M 9($BW&_J+BG-GOPEM]]&@$B XH +S"U$^$I_Q"Z8 -Y8W;Y85HN %1 MY5VC<8Y&^92KS6FD'Z;83_EN]0UKI+J("ZD4I(C!X0"E8%2#T0PV?02F.9V1 M>:I2T&A-4E5M4K BX)_2I>R20[5N&4Q9_:C/J8"D@*[@7@1RQH]@3T"/\B9I MVFPL3UU*Z8@Q8N0L]&VOSI17@6/]UKWLUOU;[+ER!&K7-93RXO)HV!15-7E9 MAZ,=%3V03G(R3&&F'3[=^MQQ9R#"D#\T0Q]'-SS-XD0AO\1E02!3 J(<%C3% M,R\ 70(Z"B0[9T<.$+Q!@EC Q> MS:1R_R2%3"LK-\Z!NX1),W)MV#G<0AY>.(U<70/:8I2 M'W0GRMNZ0S2L@(1N=5%JRWVI/Y;.'%+I!*)/A##-1M#ZF5 -# BAJ-( !Y56M?G MM9J ?9^#1&B&#RH6GX1@3,$HWK\Q[ [,O4NN8Y#C:$Z$@@?P S<,,GX]K3O* MK'PK_$;;(,]RL 7YC0+>P\_*H*\],REV8773/%1SB"=T>[400?49CLJ$ M0XL+9C(_$EI3(@*2N 9S.?='&"XHZ!_L,($70&1\MR3XHD2B_&;AM=PG&T_" MEA98)**\Y7T>LOF7(+G%N*43?C>!!9Q_BV0P_TZ= IY_"\B>?X5DM?"NY./Y M]PG'"P87JB?QOUO 2CG_MO!NU#;=DF[+][-5+"IDJ/MF X#N+ K0WJF]Q66. M.)YG!AHO!$]:&LPQ)C/A.>J:O3S&MZD KJ=)G1)^'"EU(;_NHAP_7^D[&02E MF=P/E!2_G/ED,XQO7.<4-R.Y0FLA/$ F2$Y&*UL&U:*;.+P!-TRDWQ3#8\@U M09U2A06@P]GRS@ J-C:!&J&O/&*Y=.:$[%K9/.G]0N+0SW*02*7(0K'"1,/B M!2%1F,\Q]*6^HI:A%UQQ.9AJN8QQT>*V")SKDLF\ (6\[R@K ",!^19Q6@A"*.L^"R<#&E 8\6N^.2'L?S\6\WQ#PJYA[=$Q&F9"U!$ M;J4_B-V"BE6W/X!"W*_?Y4!([!=?%.0JQCA51L$N*?.MDT)O^R(!1T9];C)5 M,$GM1:Z%8GI>.C)*DC:NE1@KWXY6.RURRUHZJ= (/%5,0$B89/@JR-(VI_T: M%F463S$F""/'F:2!1IL&GI M6TO?>'^V4C!T;4A8S:R\7D-Z@]+@B)>.5K<,E23#7ZCUHU0N!(-.ION%L9VF MPA,A1O#:+$BC; IL"20=)<0L+JHDPW)\C19D_5>RH*3VQ MRNP*:AE1H!;*;F!%8%3 GX\FI@)B+/,GH;50U-AF"/LJ65FB>7\6^FOPR=*E M%%E:MXYG4V@ %\W!5X)'"WPW(5/Q4QF_PR%& ECY&Y\B1:9Q%'$5_(1*8Z19 MK*:P!=P[$I-4D;N?PX2 2<"^!NYC,?[@Z@9@+DW[&AW/3.G*R)[0)(NJL@CG M6=KL%2W)PMJ&9=FV,J*WP.K9CKCA(<9F)()#\-TD3M6NT*1N/*:%I;/;8N:H MY4%W#T/R\\X)7J&31Q7KS5/X812A+3.WW:1K>,]/(>T#D:(_B1^_(2H%[#,' M0D:;Q=3EWK11%R;%0*G*V$* )H7A5>[(G!\-CP]/R.G9U1&Y./KY\.+S\>G/ MY,O9Q>_PLW-R=O8K/LMOUWT].KVZ+*UNG&S1ATS6T ^[!!4>^:+FOENON&2^ MN+?,_\R!"^LH^F_/*IJ'L!92W4M+.@ M;RP_#_R*,=UF'+$];+=&3.[566JN^4HW;2DK;?D4WRSAY[>$OZ=DM7JZ6GO" MVBNGK+EM*6M;DK3V\,'[UGE5'Z>N!<.+C7Z96].2X+;D.%++J1;UMYGH]C(N M=6.P.NNNQ@^M=+H1+ME9P-L"Q9?CK/)!DA;BJY.6S ]>0H+E1S+Z4CG,=_N M^GFJ@=9&BN_8^SDU,0?0(N<],'W%6??-7F5.O_#LVYK/X6+&?6WJ\T&\M/!C M,Q=X@2'F7^_R!UU;?EGSJH?*;DEF^.[-QS[_83;EG8HE7[//./'[5J2PR#QQQW MO9=OVAGB*6=5M^(&AOL(['DN5&C%\B.O&5GP9Y! #%0,DKP&*.7C'Q#T^Q!?Z#]B]^Y;D?OCK+QS@&FB'_HT?4^(/),)+$:9C8C MC9X5P-56J3"9SF72_X5*^B^/7RQ\W?F5YGCUV\71Y6M]PT2YOO*-B##I#E!M=>W)YO(GSFMW M#JA3'G_F(IGE5ZYPN<9NVZ4*+)=Y@[G<)\9L6/4Q$1P&TR5@=ASW4DLBQ"U5 MCX]H&%09A9@64-3#XW$YIC+(7FF>C>($)L&ZS[XN?[W B/W2]U8M3P<"QQ?, MT[TGZ&E[8[;))F:SKIF]?%X;_*3RFI;%!LGC"3:QN<';U1Z\T7F#WLYV8&^3 M7/&41=P**+9C239)T,_AY&T.2W4DK"U\-D>XZX%1?5C2?#XB;D"T7DSGEZ/3 MLZ]'?Y#CTV%+6'];*>$55W_=H=_T[:;!V&HA10KCOKYM])KTNAEX-D;$2\!9 M2V9]FJYGUU<2V-AY"66^X=O9BTGWTAZY]*%+,AS122A:=O.VE"/>A/7V^L[J M+O_UV.EE1/U:DWACC#?&V#1-R>O\OWO.&(X$#\@)OZ8A.0L"X?-D.[8]ZJ&3 MS5X.+!-P%)%5FQW% +7=BL=N/[1M(S2OG7W<9:^-W_CSB0F*9"%A_T//B]D4 ML= ;9>,0?OP_4$L#!!0 ( #))$5?11-/.T!, &A, 7 8G)H8S(P M,#4W-CY2>PTZSJ. MF;N)Q,M.9CQ )B;BB")8@)>O^^MGG "!!/9R7G;IKZM7&$@GB<;#/:Q_0 MS[-ZGK_XUW\1XGFF9,J?\+G6=:Y>/'_@?ON+?QD.Q;E.5&%5*FIS)%Y61J:5 M3J=*O-:%+!(M<_'>Y$VM32'>%,G(/O[4E*M*3[-:'#Q[]E@,Q>'^X'0K>.!7\CS ML4E78CQ-3&ZJG_:^F_#/GK#U*E<_[4U,40\G*RO>JJ6X-'-9 M_' L^+[5_U1'XF"_K(]%K:[JH9'NM:/'LV.GC^8-?HFS)_/JZZECN? MVR:>&YGVRZJ9J0H KDI32=8-6:3B(E.%F:O_8441)T6!34N4>*4FNM"U7BAQ M,JV48IV9F$KX;FHC3I+?&EVIK@==B),\'YY*FXD/E2RL3&B8SY'1]]\=_'7_ M^%M(ASL\$KI&;\EVB?$"K691L3!@,*P7P/??/3T\>')L!291K7 ; IE ,2JZ&B6@7+VR]GE__XWM1B(4PP$,!1:#L1),VTLS.&3@;.%+)G#8[$% M;S^^E3:5O\%D7_Y\>7\+_-H&IV?GY_C_7U1H@5,'FYJT@W8O7R8$)CK#LPC\2%3HJQ, M:8J,2( )A1:U2O70IB)D"5ZN-)S "I?8?3]IP+;E'/_ MG3I![C&F8C!U:T_,O)3%RLD&O2YTBDE8L"V,YCJ#%YMFA#H2]1@!!DL#F_A253.5 XSG3FZT M_C?67.3J2MM!']U)4U7 8D[(I98D;0 CQWAC:1D3

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end